Skip to main content
SpringerLink
Log in

Vortioxetine in major depressive disorder: a guide to its use in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Vortioxetine (Brintellix®), a serotonin transporter inhibitor and modulator of serotonin receptor activity, extends the available options for treating major depressive disorder (MDD). It is generally effective as acute treatment (including in elderly patients), in relapse prevention and as maintenance treatment in patients with MDD. Vortioxetine improves cognitive function in patients with MDD and is generally well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433–42.

    Article  CAS  PubMed Central  Google Scholar 

  2. Pehrson AL, Leiser SC, Gulinello M, et al. Treatment of cognitive dysfunction in major depressive disorder-a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur J Pharmacol. 2015;753:19–31.

    Article  CAS  PubMed  Google Scholar 

  3. Brintellix® (vortioxetine tablets): EU summary of product characteristics. London: European Medicines Agency; 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf.

  4. Brintellix® (vortioxetine tablets): US prescribing information. Deerfield: Takeda Pharmaceuticals America, Inc.; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf.

  5. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–21.

    Article  CAS  PubMed  Google Scholar 

  6. Areberg J, Luntang-Jensen M, Søgaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;110(4):401–4.

    Article  CAS  PubMed  Google Scholar 

  7. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190–8.

    Article  CAS  PubMed  Google Scholar 

  8. Sánchez C, Pehrson AL, Bétry C, et al. Vortioxetine (Lu AA21004), an investigational multimodal antidepressant: differentiation from currently used antidepressants in preclinical rodent models [abstract]. Biol Psychiatry. 2013;9(Suppl 1):106S–7S.

    Google Scholar 

  9. Sánchez C. Lu AA21004, a novel multimodal antidepressant. Neurotherapeutics. 2012;9(3):681–2.

    Google Scholar 

  10. Li Y, Raaby KF, Sánchez C, et al. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res. 2013;256:520–8.

    Article  CAS  PubMed  Google Scholar 

  11. Browning M, Smith J, Cohen S, et al. Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants [abstract no. W12]. In: 53rd Annual Meeting of the American College of Neuropsychopharmacology. 2014.

  12. Dawson G, Conen S, McKie S, et al. Effects of vortioxetine on resting-state activity in spbjects remitted from depression and healthy controls [abstract no. M155]. In: 53rd Annual meeting of the American College of Neuropsychopharmacology. 2014.

  13. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313–21.

    Article  CAS  PubMed  Google Scholar 

  14. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589–600.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015. doi:10.1007/s00213-014-3839-0.

    PubMed Central  PubMed  Google Scholar 

  16. Nishimura A, Hirochi K, Asari K, et al. A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine 5, 10, and 20 mg in adults with major depressive disorder [abstract no. 106]. In: 27th Annual US Psychiatric and Mental Health Congress. 2014.

  17. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953–9.

    Article  CAS  PubMed  Google Scholar 

  18. Jacobsen P, Mahableshwarkar AR, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder [abstract no. NR9-06]. In: 166th Annual Meeting of the American Psychiatric Association. 2013.

  19. Mahableshwarkar A, Jacobsen PL, Serenko M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder [abstract no. NR9-02]. In: 166th Annual Meeting of the American Psychiatric Association. 2013.

  20. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482–91.

    Article  CAS  PubMed  Google Scholar 

  21. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138–49.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217–26.

    Article  CAS  PubMed  Google Scholar 

  23. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015. doi:10.1038/npp.2015.52.

    PubMed  Google Scholar 

  25. Vieta E, Loft H, Mahableshwarkar A, et al. The efficacy of vortioxetine in the treatment of patients with major depressive disorder (MDD) in short-term placebo-controlled studies: a meta-analysis of 11 studies [abstract no. P.2.f.023]. Eur Neuropsychopharmacol. 2014;24(Suppl 2):S465–6.

    Article  Google Scholar 

  26. US National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 12 May 2015.

  27. Baldwin D, Loft H, Jacobsen P, et al. The efficacy of vortioxetine in treating patients with severe depression or with depression and high level of anxiety symptoms [abstract no. P.2.f.020]. In: 27th European College of Neuropsychopharmacology Congress. 2014.

  28. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–23.

    Article  PubMed  Google Scholar 

  29. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717–24.

    Article  CAS  PubMed  Google Scholar 

  30. Filippov G, Christens PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder [abstract no. P.2.b.011]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S325.

    Article  Google Scholar 

  31. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2013;29(1):36–44.

    Article  PubMed Central  Google Scholar 

  32. Jacobsen P, Harper L, Serenko M, et al. A phase 3, long-term, open-label extension study evaluating the safety and tolerability of 15 and 20 mg vortioxetine in subjects with major depressive disorder [abstract no. P-23-017]. Int J Neuropsychopharmacol. 2014;17(Suppl 1):97–8.

    Google Scholar 

  33. Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder [abstract no. P.2.c.010]. Eur Neuropsychopharmacol. 2012;22(Suppl 2):S255–6.

    Article  Google Scholar 

  34. Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenalin reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Wang G, Gislum M, Filippov G, et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015;31(4):785–94.

    Article  CAS  PubMed  Google Scholar 

  36. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (Oxf). 2012;26(11):1408–16.

    Article  Google Scholar 

  37. Jacobsen P, Mahableshwarkar AR, Chen Y, et al. Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction [abstract no. P.2.f.022]. Eur Neuropsychopharmacol. 2014;24(Suppl 2):S464–5.

    Article  Google Scholar 

  38. Jacobsen P, Clayton A, Mahableshwarkar A, et al. The effect of vortioxetine in sexual dysfunction in adults with major depressive disorder or generalized anxiety disorder [abstract no. 35]. In: The American Society of Clinical Psychopharmacology Annual Meeting. 2014.

  39. Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014;28(9):855–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: M. Hahn, Vitos Rheingau, Eltville, Germany; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India.

Disclosure

This article was updated from CNS Drugs 2014;28(9):855–74 [39] by salaried employees of Adis/Springer. The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Karly P. Garnock-Jones & Katherine A. Lyseng-Williamson

Authors
  1. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garnock-Jones, K.P., Lyseng-Williamson, K.A. Vortioxetine in major depressive disorder: a guide to its use in the EU. Drugs Ther Perspect 31, 221–228 (2015). https://doi.org/10.1007/s40267-015-0217-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0217-x

Keywords

Search

Navigation